

# Cleaved-Notch 2 (D1733) Polyclonal Antibody

Catalog # AP63144

#### **Product Information**

Application WB, IHC-P, IF Primary Accession 004721

**Reactivity** Human, Mouse, Rat

HostRabbitClonalityPolyclonalCalculated MW265405

#### **Additional Information**

**Gene ID** 4853

Other Names NOTCH2; Neurogenic locus notch homolog protein 2; Notch 2; hN2

**Dilution** WB~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. Immunohistochemistry:

1/100 - 1/300. ELISA: 1/40000. Not yet tested in other applications. IHC-P~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/40000. Not yet tested in other applications. IF~~IF: 1:50-200 Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/40000.

Not yet tested in other applications.

Format Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium

azide.

Storage Conditions -20°C

#### **Protein Information**

Name NOTCH2 ( HGNC:7882)

**Function** Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1),

Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus (PubMed:21378985, PubMed:21378989). Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and

positively regulates RANKL-induced osteoclast differentiation

(PubMed:29149593). Positively regulates self-renewal of liver cancer cells

(PubMed:25985737).


**Cellular Location** [Notch 2 extracellular truncation]: Cell membrane; Single-pass type I

membrane protein


## **Background**

Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus (PubMed:21378985, PubMed:21378989). Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL- induced osteoclast differentiation (PubMed:29149593). Positively regulates self-renewal of liver cancer cells (PubMed:25985737).


### **Images**




Immunofluorescence analysis of rat-lung tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of rat-lung tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of rat-kidney tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-kidney tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunohistochemical analysis of paraffin-embedded Human-liver tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.


Immunohistochemical analysis of paraffin-embedded Rat-lung tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium




citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-spleen tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Mouse-lung tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Mouse-kidney tissue. 1,Cleaved-Notch 2 (D1733) Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.



Western Blot analysis of various cells using Cleaved-Notch 2 (D1733) Polyclonal Antibody diluted at 1:500



Western Blot analysis of 293 cells using Cleaved-Notch 2 (D1733) Polyclonal Antibody diluted at 1:500



# The picture was kindly provided by our customer,antibody was diluted at 1:500

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.